CTLA4 and neoplasm: CT26 subcutaneous inoculation model mice treated with DSP-0509 5 mg/kg i.v. weekly combined with anti-CTLA-4 antibody 200 μg i.p. twice weekly showed significant tumor growth inhibitory activity compared to the vehicle and anti-CTLA-4 antibody treated groups (Figure 5A).